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Abstract
Background: Initial staging of gastric cancer consists of computed tomography (CT) and gastroscopy. In locally
advanced (cT3–4) gastric cancer, fluorodeoxyglucose positron emission tomography with CT (FDG-PET/CT or PET)
and staging laparoscopy (SL) may have a role in staging, but evidence is scarce. The aim of this study is to evaluate
the impact and cost-effectiveness of PET and SL in addition to initial staging in patients with locally advanced
gastric cancer.
Methods: This prospective observational cohort study will include all patients with a surgically resectable, advanced
gastric adenocarcinoma (cT3–4b, N0–3, M0), that are scheduled for treatment with curative intent after initial
staging with gastroscopy and CT. The modalities to be investigated in this study is the addition of PET and SL. The
primary outcome of this study is the proportion of patients in whom the PET or SL lead to a change in treatment
strategy. Secondary outcome parameters are: diagnostic performance, morbidity and mortality, quality of life, and
cost-effectiveness of these additional diagnostic modalities. The study recently started in August 2017 with a
duration of 36 months. At least 239 patients need to be included in this study to demonstrate that the diagnostic
modalities are break-even. Based on the annual number of gastrectomies in the participating centers, it is estimated
that approximately 543 patients are included in this study.
Discussion: In this study, it is hypothesized that performing PET and SL for locally advanced gastric
adenocarcinomas results in a change of treatment strategy in 27% of patients and an annual cost-reduction in the
Netherlands of €916.438 in this patient group by reducing futile treatment. The results of this study may be
applicable to all countries with comparable treatment algorithms and health care systems.
Trial registration: NCT03208621. This trial was registered prospectively on June 30, 2017.
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Background
Gastric cancer is the fifth most common type of cancer
worldwide [1]. In Western countries, curative treatment
consists of gastrectomy with perioperative chemotherapy
[2–4]. Unfortunately, the prognosis of patients who undergo
curative treatment remains relatively poor, with a 5-year
overall survival rate of 20–40%. The main cause for this
poor prognosis is tumor recurrence [2, 5]. The poor progno-
sis, treatment-related morbidity and mortality, and impair-
ments in quality of life result in a high disease burden [6].
The standard diagnostic work-up of patients with gastric
cancer includes a gastroscopy to assess tumor size and lo-
cation and to obtain tissue to characterize the tumor. Fur-
thermore, computed tomography (CT) of the thorax and
abdomen is performed to detect metastases and evaluate
local resectability. However, the accuracy of CT for detect-
ing metastatic disease (M1) or local irresectability (T4b) is
low: the sensitivity to detect peritoneal metastases is 22%–
33%, to detect distant metastases is 14%–65% and to de-
tect T4b disease is 5%–69% [7–10]. Consequently, two un-
desirable situations may occur in practice:
1. Unexpected intraoperative peritoneal metastases or
local tumor irresectability are found at the onset of
gastrectomy.
2. Undetected distant metastases presenting shortly
after treatment with curative intent (neoadjuvant
chemotherapy and/or surgery).
In both situations, patients undergo a futile treatment,
probably leading to a reduced quality of life and an in-
crease in health care costs.
A recent study from the United States investigated the
additional staging capacities of fluorodeoxyglucose posi-
tron emission tomography with CT (PET) and staging
laparoscopy (SL) in gastric cancer. In this study, combin-
ation of PET and SL identified additional metastases in
27% of patients: distant metastases by PET in 10% of pa-
tients, and peritoneal metastases by SL in 19% of patients
(with an overlap of 2%) [11].To reduce the number of pa-
tients undergoing futile treatment, the new Dutch guide-
lines for the treatment of gastric cancer recently included
PET and SL in the staging algorithm of locally advanced
(cT3–4) tumors“(http://www.oncoline.nl/maagcarcinoom)
”. However, this guideline concludes that the evidence for
both staging modalities is weak, and additional studies are
needed to further investigate the cost-effectiveness and
applicability of routinely adding PET and SL to the staging
of locally advanced gastric cancer.
Aim of the study
The aim of this study is to evaluate the clinical impact
and cost-effectiveness of PET and SL in addition to ini-
tial staging by CT and gastroscopy in patients with lo-
cally advanced (cT3–4) gastric cancer.
Methods
Objectives
The primary outcome of this study is the proportion of
patients in whom PET and SL lead to a change in treat-
ment strategy. The accuracy of each modality will be an-
alyzed separately. Secondary outcome parameters are
diagnostic performance (sensitivity, specificity, positive
and negative predictive value), morbidity and mortality,
quality of life, cost reduction and cost-effectiveness. The
hypothesis of this study is that adding PET and SL to
additional staging in these patients will lead to a change
of treatment strategy in 27% of patients, leading to an
annual cost reduction in the Netherlands of €916.438 by
reducing futile treatment.
Study design
The study design is a prospective observational cohort
study. All patients with a locally advanced tumor who
are candidates for gastrectomy with curative intent will
be invited to participate in this study. A locally advanced
tumor is defined as a transmural tumor invading the
outer layer of the stomach (cT3–4 according to the 7th
edition of the American Joint Committee on Cancer
TNM staging system [12]), objectified on CT [13].
Study population
The study population consists of patients with a surgi-
cally resectable, advanced gastric adenocarcinoma (cT3–
4b, N0–3, M0), who are scheduled for treatment with
curative intent after initial staging with gastroscopy and
CT. Patients’ inclusion and exclusion criteria are defined
as follows:
Inclusion criteria:
• Histologically proven adenocarcinoma of the stom-
ach or esophagogastric junction (Siewert type III) as ob-
served by gastroscopy.
• Underwent evaluation with CT of the abdomen and
chest.
• Surgically resectable, advanced gastric cancer (cT3–
4b, N0–3, M0), as determined by the multidisciplinary
team (MDT).
• Intention to perform a potentially curative gastrec-
tomy with or without perioperative treatment.
Exclusion criteria.
• Siewert type I-II esophagogastric junction tumor.
• Unfit or unwilling to undergo surgery.
Study protocol
Initial staging
Initial staging should be performed according to national
guidelines, including at least gastroscopy with tumor bi-
opsies and a CT of the thorax and abdomen. Endoscopic
Ultrasonography (EUS) may be performed optionally. In
case of a cT3–4 tumor (defined as a transmural tumor
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invading the outer layer of the stomach) [13], patients
will be invited to participate in this study and thereby
give permission to collect and analyze their data. Differ-
entiation between cT2 and cT3 tumors is not always
possible with initial staging. In case of considerable
doubt whether a tumor is cT2 or cT3, patients will be
included if deemed appropriate by the MDT. As part of
a side study, an expert panel will review all CT-scans to
reach consensus on the clinical T-stage.
Patient inclusion
If eligible for treatment with curative intent by the
MDT, patients will be invited to participate in this study.
Patients will be informed and included at the outpatient
department of one of the Dutch investigational centers
or its associated hospitals. As this study does not allo-
cate patients to study interventions other than usual
care, as recommended by the new Dutch guidelines, this
study does not fall within the Medical Research Involv-
ing Human Subjects Act (WMO). Patients will be asked
to sign informed consent form to confirm that they
know that their data will be anonymously used for re-
search purposes, and approve to fill out quality of life
questionnaires, making use of the previously reported
infrastructure of POCOP [14].
Investigated modalities
The modalities to be investigated in this study are both
PET and SL in addition to the initial staging with gas-
troscopy and CT of patients with an advanced gastric
cancer (cT3–4). Patients will undergo PET and SL ac-
cording to the recently revised Dutch guidelines [15]. All
patients will first undergo a PET, and if the PET does
not show evidence of distant metastases a SL will be per-
formed (Fig. 1). PET or SL may be omitted if it is
deemed appropriate by the MDT or if it appears that a
patient is not able to undergo one of both modalities.
FDG-pet/CT
Preparation of patients for PET, and scanning and image re-
construction will be performed according to the institu-
tional protocols of the participating centers, preferably
incorporating guidelines of the European Association of
Nuclear Medicine (EANM) / EANM Research Ltd. (EARL)
and/or Netherlands Association of Nuclear Medicine
(NVNG) [16]. In general, patients should refrain from
strenuous exercise, and fast for at least 4 to 6 h before the
injection of FDG. Patients should be pre-hydrated by drink-
ing approximately 1 L of water in the 2 h before injection.
Fasting blood glucose should preferably be below 11 mmol/
L. After the injection of FDG, patients will remain seated or
lying, and silent for 1 h in a warm room. A full body PET
scan will be performed 60 min (range 55–75 min) after the
injection of FDG, accompanied by a CT at the same scan-
ning range. Scans are read, interpreted and reported by the
nuclear medicine physicians of the respective participating
centers. The report generally includes information regard-
ing the FDG-avidity of the primary tumor and/or locoregio-
nal lymph nodes, and suspicion of distant metastases. For
this study, the maximum standardized uptake values (SUV-
max, corrected for body weight) of the primary tumor will
also be registered. If the PET identifies new lesions that are
possible metastases, a histological of cytological biopsy and/
or additional imaging of a lesion is advised to confirm or
exclude metastases.
Staging laparoscopy
SL will be performed after the PET, prior to the initi-
ation of treatment, and should be performed by or under
supervision of a gastrointestinal or oncological surgeon.
During staging laparoscopy, the goals are to evaluate the
resectability of the primary tumor (T-stage) and to
evaluate the presence or absence of peritoneal metasta-
ses. To evaluate the resectability of the tumor, a thor-
ough inspection of the region of the stomach and tumor
along with surrounding organs will be performed. In
case of a tumor localized at the posterior wall of the
stomach, it is advised to open the omental bursa and in-
spect it accordingly. To evaluate the presence or absence
of peritoneal metastases, all quadrants of the peritoneal
cavity and Douglas’ pouch will be inspected. In case of
suspicious macroscopic lesions, biopsies will be taken
and sent for histological review. When macroscopic le-
sions are present, all thirteen regions of the abdomen
Fig. 1 Study Flowchart. CT: computed tomography; cT3–4: advanced tumor with clinical T-stage 3 or 4.; MDT: Multidisciplinary Team; PET:
fluorodeoxyglucose positron emission tomography with CT; SL: Staging Laparoscopy
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will be evaluated and the peritoneal cancer index (PCI)
will be scored [17]. Cytology of the peritoneal cavity
should be performed (500cm3 dispersed throughout all
quadrants and Douglas’ pouch) as it is a promising
prognostic factor with possible implications for
treatment in the future [18, 19].
MDT
Ideally, patients will be discussed in a first MDT after
initial staging with gastroscopy and CT of the thorax
and abdomen, and in a second MDT after additional sta-
ging with PET and SL (Fig. 1). In practice, in some pa-
tients the first or second MDT will be skipped and
patients will proceed to additional staging or treatment
without intervention of MDT’s. An included patient
should be discussed in at least one MDT. Occasionally,
an additional diagnostic modality will be required and
the patient is discussed during a third MDT.
Treatment
If the tumor is deemed to be resectable, patients will be
scheduled for treatment. Treatment will not be initiated
before completion of staging according to the Dutch
guidelines, including PET and SL [15]. There are no add-
itional restrictions to the further treatment strategy, such
as chemotherapy regimen or type/approach of resection.
Outcome measurements
The primary outcome of this study is the proportion of
patients in whom PET and/or SL leads to a change in
treatment strategy. This includes the proportion of pa-
tients in whom surgery with curative intent is prevented,
and the proportion of patients in whom the chemother-
apy regimen is changed or omitted. Secondary outcome
parameters include cost-effectiveness, modality-specific
performances (diagnostic performance of both modal-
ities, incidental findings on PET), patients’ extra burden
of the diagnostic modalities (morbidity and mortality,
diagnostic delay, number of extra MDT’s held), and
overall quality of life of patients (EORTC Quality of Life
questionnaires).
Sample size calculation
Based on previous literature it is expected that 27% of pa-
tients will have a change in treatment strategy [11]. Taking
a safety margin of 5% into account (thus at least 22% of
patients will have a change in treatment strategy), an alpha
of 0.05 and a power of 0.80, at least 239 patients need to
be included in this study to demonstrate that performing
a combination of both diagnostic modalities is cost-
effective. Based on the yearly number of gastrectomies
performed in the participating centers, approximately 543
patients are expected to be eligible for the study in
36 months.
Statistical analysis
The primary outcome measures, change in treatment
strategy of PET and SL, will be presented as a percentage.
To evaluate the performance of PET and SL, sensitivity
and specificity will be calculated. A separate analysis will
be performed to assess whether both diagnostic modalities
are accurate for various subgroups, for instance tumor
types (Lauren classification: diffuse, intestinal and mixed).
The quality of life of patients in this study will be com-
pared to previous data from literature and to a retrospect-
ive cohort of patients who did not undergo PET and SL.
Differences are tested using linear mixed-effects modeling,
taking relevant patient characteristics into account. Miss-
ing values will be imputed using multiple imputation tech-
niques. Statistical significance is defined as p < 0.05. Cost-
effectiveness will be calculated, taking all relevant health-
related costs into account, including costs arising from
complications of medical treatment, and additional diag-
nostics arising from false-positive findings on PET. A
model (Fig. 2) will be developed to compare health care
costs with only CT. A budget impact analysis (BIA) will
be performed, adhering to the newest guidelines and ap-
plying the societal, health insurance/third party payer and
health care perspectives. Analyses will be performed for
the combination of PET and SL and for both treatment
modalities separately.
Time schedule
The study recently started on 01–08-2017, and will last
for 36 months. After the start of the study, the first
30 months will consist of inclusion and follow-up of the
patients. The last 6 months will consist of follow-up and
analysis of results. The study will end at 01–08-2020.
Discussion
The PLASTIC study is a prospective observational cohort
study evaluating the impact and cost-effectiveness of PET
and SL in addition to initial staging by CT and gastroscopy
in patients with locally advanced gastric cancer. The new
Dutch guidelines recently included these staging modal-
ities for staging locally advanced gastric cancer but recom-
mended additional studies to be performed.
Until recently, the role of PET in the staging of
gastric cancer has been limited. Indeed, during initial
staging of gastric cancer, the sensitivity and specificity
of PET are not better than that of CT for lymph node
metastases, liver metastases and peritoneal metastases
[7–9, 15]. However, for patient with locally advanced
tumors, PET may be able to find additional distant
metastases which were not detected during initial sta-
ging with CT. This was recently reported in a single
study from the United States by Smyth et al., who
prospectively evaluated the utility of PET and SL in
patients with locally advanced gastric cancer [11].
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They found that PET is able to detect additional dis-
tant metastases in 10% of patients, resulting in an es-
timated cost reduction of $13.000 per patient.
Moreover, they concluded that PET is most cost-
effective if performed prior to SL [11]. However, the
cost-effectiveness analysis was performed retrospect-
ively and might not be applicable to health care sys-
tems outside the US.
SL prior to gastrectomy has been broadly applied
to diagnose peritoneal metastases. Studies evaluating
the percentage of patients who benefit from SL are
abundant, with percentages varying between 16 and
38% [10, 20–27]. Unfortunately, high quality evi-
dence supporting cost-effectiveness is not available.
The PLASTIC study will be the first study to pro-
spectively investigate the cost-effectiveness of SL in
combination with PET.
In this study, patients will first undergo a PET,
followed by a SL if PET does not show distant metasta-
ses. If distant metastases found on PET are confirmed by
biopsy or additional imaging, SL will be omitted. This
order was chosen as it is more applicable in clinical
practice for the following reasons:
 PET is non-invasive, whereas a SL is invasive and is
accompanied by a higher risk of adverse events for
the patients.
 Assessing the PET after SL will be less reliable, due
to uptake of FDG in postoperative inflammation.
 PET scans can be scheduled more easily and
probably results in less diagnostic delay.
 In a theoretical model from a previous study, first
performing PET resulted in more cost savings
compared to a SL-first approach (difference $2168
per patient) [11].
This study aims to include patients with locally advanced
(cT3–4) gastric cancer, but the accuracy of CT for deter-
mining T-stage is low [8]. This could result in the unin-
tended inclusion of early stage (T2) tumors or failure to
include truly advanced tumors. Nevertheless, these flaws re-
flect current practice. To reduce the impact of these
current limitations, an expert panel will review all CT-scans
to reach consensus on the clinical T-stage as a side study.
The current study is relevant, as the addition of PET and
SL may prevent futile gastrectomies, which are associated
with considerable morbidity, mortality, reduction in quality
of life and costs [28–30]. On the other hand, the number of
prevented gastrectomies should exceed a certain level, as
PET and SL are accompanied by costs and possible risks
for the patient (ionizing radiation, surgical complications)
as well. The results of this study will be implemented in an
updated version of the Dutch guidelines, but may also be
applicable to all other Western countries with comparable
treatment algorithms and health care systems.
By performing staging laparoscopy before starting
treatment, a side effect of this study might be that more
patients with peritoneal carcinomatosis will be detected.
Recent studies have shown that there may be a role for
hyperthermic intraperitoneal chemotherapy (HIPEC)
and cytoreductive surgery in these patients [31, 32]. Pa-
tients with peritoneal carcinomatosis as detected in this
study may therefore be included in HIPEC trials [33].
This prospective observational cohort study will evalu-
ate the impact and cost-effectiveness of FDG-PET/CT
and staging laparoscopy in addition to initial staging by
CT and gastroscopy in patients with locally advanced
gastric cancer. It is hypothesized that in 27% of patients
a change in treatment strategy will occur, and that the
annual cost reduction in the Netherlands will be ap-
proximately €916.438.
Fig. 2 Decision tree for PET and SL. CT: computed tomography; PET: fluorodeoxyglucose positron emission tomography with CT; SL: Staging Laparoscopy
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Trial status
As this study does not fall under the Medical Research
Involving Human Subjects Act (WMO), a waiver for
ethical approval (16–633/C) was obtained from the eth-
ical review board of the UMC Utrecht. Recruitment of
patients started in August 2017.
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